Phase 2, randomized, double‐blind, placebo‐controlled, 4‐week study to evaluate the safety and efficacy of OPA‐ 15406 (difamilast), a new topical selective phosphodiesterase type‐4 inhibitor, in Japanese pediatric patients aged 2–14 years with atopic dermatitis

The safety and efficacy of OPA‐15406 (international non‐proprietary name, difamilast; also referred to as MM36), a new topical, selective phosphodiesterase type‐4 inhibitor, in Japanese pediatric patients with atopic dermatitis aged 2–14 years were evaluated in a phase 2, randomized, double‐blind, v...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeki, Hidehisa, Baba, Naoko, Oshiden, Kazuhide, Abe, Yuji, Tsubouchi, Hidetsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972691/
https://www.ncbi.nlm.nih.gov/pubmed/31713267
http://dx.doi.org/10.1111/1346-8138.15137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972691/
https://www.ncbi.nlm.nih.gov/pubmed/31713267
http://dx.doi.org/10.1111/1346-8138.15137

Ejemplares similares